KDM6B and metabolic dysfunction-associated steatotic liver disease: The mRNA and protein expressions of KDM6B were significantly reduced in human NAFLD samples compared to the normal population, and fibroblast growth factor-21 (FGF21) improved hepatic autophagy and lipolysis through KDM6B in NAFLD mice [37].